Focused On-demand Library for Prolactin receptor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P16471

UPID:

PRLR_HUMAN

Alternative names:

Alternative UPACC:

P16471; B2R882; D1MDP1; Q16354; Q8TD75; Q8TD78; Q96P35; Q96P36; Q9BX87; Q9UHJ5

Background:

The Prolactin Receptor, encoded by the gene with accession number P16471, plays a pivotal role in the biological response to prolactin, a hormone crucial for lactation and reproductive functions. This receptor's activation influences various cellular processes, including the survival of spermatozoa by inhibiting sperm capacitation. Notably, certain isoforms of this receptor, such as isoform 4 and 6, are incapable of transducing prolactin signaling, highlighting the complexity of its function.

Therapeutic significance:

The Prolactin Receptor's involvement in diseases such as Multiple fibroadenomas of the breast and Hyperprolactinemia underscores its potential as a target for therapeutic intervention. Understanding the receptor's role in these conditions could lead to innovative treatments for prolactin-related disorders, offering hope for patients suffering from these diseases.